New combo therapy aims to boost survival in tough esophageal cancer cases
NCT ID NCT05189730
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether adding the immunotherapy drug tislelizumab to chemotherapy after standard chemoradiation can improve outcomes for people with locally advanced esophageal cancer who are at high risk. About 80 participants will receive the combination before surgery, then get more treatment based on their results. The goal is to see if this approach can help high-risk patients live longer while avoiding extra side effects for those at lower risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) combined with paclitaxel and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this could lead to a more personalized treatment approach for esophageal cancer, helping high-risk patients live longer while sparing low-risk patients from unnecessary side effects.
What could go wrong
This is an early-phase exploratory study with only 80 participants, so results may not apply broadly. The combination therapy also carries risks of side effects from both immunotherapy and chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China